56.3 F
New York
Tuesday, May 17, 2022

Moderna [NASDAQ: MRNA] Lost Bid To Arbutus Patent On Vaccine Technology

Must read

Moderna Inc. [NASDAQ: MRNA] has lost its efforts to discredit U.S. patent owned by Arbutus Biopharma [NASDAQ: ABUS], which has hampered Modernna’s next-generation vaccine efforts, including a coronavirus vaccine.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Moderna Inc. has argued that the Arbutus patent known as ‘069 patent’ should be rejected because it described obvious concepts. But the administrative court run by the US patent and trademark office refused to revoke the patent.

The 069 patent is related to lipid nanoparticle (LNP) that allows the human body to make its own therapeutics protein. Lipid nanoparticle technology is very important for Moderna Inc for the development of vaccines.

Moderna Inc considered Arbutus an obstacle in the vaccine development effort. The court order is disappointing but it doesn’t have an immediate financial impact on the company because of this decision.

Shares of Moderna Inc. traded down 9.49% during the trading of Friday. It had a trading volume of 29.29 million as compared to the average volume of 25.91 million. Moderna Inc has recorded sales of 52.60 million.

If we look at its profitability, its return on investment is 44.90%, return on assets is -29.20%, and return on equity is -37.40%. In the past 52-weeks of trading this company’s stocks has fluctuated between the low of 552.77% and a high of -20.88%.

More articles

Latest article